EAM Investors’s Enzo Biochem, Inc. ENZ Stock Holding History

EAM Investors’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-203,962	Closed	-$734K	–	328
2019 Q3	$734K	Buy	203,962 +25,023	+14%	+$88.6K	0.19%	205
2019 Q2	$603K	Buy	+178,939	New	+$630K	0.15%	235
2017 Q4	–	Sell	-214,155	Closed	-$2.24M	–	355
2017 Q3	$2.24M	Buy	214,155 +54,225	+34%	+$602K	0.3%	163
2017 Q2	$1.77M	Sell	159,930 -6,127	-4%	-$57.1K	0.29%	157
2017 Q1	$1.39M	Sell	166,057 -93,857	-36%	-$661K	0.22%	166
2016 Q4	$1.8M	Sell	259,914 -7,454	-3%	-$47.6K	0.24%	211
2016 Q3	$1.36M	Hold	267,368	–	–	0.18%	224
2016 Q2	$1.6M	Buy	+267,368	New	+$1.48M	0.24%	198
2014 Q4	–	Sell	-685,903	Closed	-$3.53M	–	366
2014 Q3	$3.53M	Hold	685,903	–	–	0.72%	8
2014 Q2	$3.6M	Buy	685,903 +170,712	+33%	+$738K	0.68%	6
2014 Q1	$2.14M	Buy	+515,191	New	+$1.77M	0.39%	78

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

EAM Investors's ENZ Position: Q4 2019 in Review

EAM Investors sold out of Enzo Biochem, Inc. (ENZ) in Q4 2019, closing a stake of 203,962 shares — an estimated $734K sold.

EAM Investors first reported a position in ENZ in Q1 2014 and held it in 11 quarters. The position peaked at $3.6M in Q2 2014. 81 funds tracked by Wall St. Rank hold ENZ as of Q4 2019.

EAM Investors reported no remaining Enzo Biochem, Inc. position as of Q4 2019 after selling out during the quarter.
EAM Investors sold 203,962 Enzo Biochem, Inc. shares in Q4 2019, an estimated $734K.
EAM Investors first reported a position in Enzo Biochem, Inc. in Q1 2014 and held it in 11 quarters.
EAM Investors's Enzo Biochem, Inc. position peaked at $3.6M in Q2 2014.
81 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q4 2019.

Based on EAM Investors's 13F filing for Q4 2019, filed 11 Feb 2020.